NEW YORK (TheStreet) -- Biotech, biotech, biotech. That's been the talk of Wall Street for all of 2013, with mergers and acquisitions happening every other day. That's why TheStreet's Jim Cramer and "Mad Money" Research Director Nicole Urken discussed which biotechs could be the next to merge.

Both Trius Therapeutics ( TSRX) and Cubist Pharmaceuticals ( CBST) are up by double-digit percentage points after their merger.

Cramer still expects a company to bid for Alexion Pharmaceuticals ( ALXN).

He added that while there are a lot of IPOs coming to the market, he continues to like the "four horsemen," of which he means Celgene ( CELG), Regeneron Pharmaceuticals ( REGN), Gilead Sciences ( GILD), and Biogen ( BIIB).

Biotech has been hot for several reason, Urken said, citing an improved Food and Drug Administration process, a more risk-absorbing investor base and a stronger pipeline of products. Also, these companies continue to grow at strong rates without the macro headwinds slowing them down.

Specifically, Cramer said there's one company in the sector he really loves: Celgene. The company has a ton of products in its pipeline and is actually cheap when looking at it on a valuation basis.

He also said Gilead Sciences could be a good company to look at it if its hepatitis-C drug pans out the way some are expecting.

-- Written by Bret Kenwell in Petoskey, Mich.

Bret Kenwell currently writes, blogs and also contributes to Robert Weinstein's Weekly Options Newsletter. Focuses on short-to-intermediate-term trading opportunities that can be exposed via options. He prefers to use debit trades on momentum setups and credit trades on support/resistance setups. He also focuses on building long-term wealth by searching for consistent, quality dividend paying companies and long-term growth companies. He considers himself the surfer, not the wave, in relation to the market and himself. He has no allegiance to either the bull side or the bear side.

More from Opinion

These 5 Tech Giants Still Aren't That Expensive

These 5 Tech Giants Still Aren't That Expensive

Intel CEO Brian Krzanich's Ouster Proves CEOs Aren't Above the Rules

Intel CEO Brian Krzanich's Ouster Proves CEOs Aren't Above the Rules

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Red Hat CFO Tells TheStreet: Tech Trends Are Still in Our Favor

Throwback Thursday: Intel Edition

Throwback Thursday: Intel Edition

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others

Intel's Next CEO Should Try Harder to Protect Its Flanks Against AMD and Others